We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
GLOBETECH PUBLISHING LLC

Download Mobile App




Low-Dose CT Screening Does Not Damage Chromosomal DNA

By MedImaging International staff writers
Posted on 01 Apr 2020
Print article
Lung cancer screening using low-dose chest computed tomography (CT) does not biologically affect human DNA, according to a new study.

Researchers at Hiroshima University (Japan) and Fukushima Medical University (FMU; Japan) conducted a study that compared DNA in 107 patients who underwent low-dose chest CT with that of 102 patients who had standard-dose chest CT; the median effective radiation dose of low-dose CT was 1.5 millisieverts (mSv), while that of the standard CT dose was 5.0 mSv. In addition, blood samples were obtained before and 15 minutes after CT to identify DNA double-strand breaks and chromosome aberrations (CAs) in peripheral blood lymphocytes.

The results revealed that the number of double-strand DNA breaks and CAs increased after the standard dose CT examination, but that the number of double-strand breaks and CAs before and after low dose CT remained the same. The researchers stressed that while the study does not endorse lung cancer screening with low-dose CT, its results could allay concerns over a potential increase in radiation-related cancer risk related to screening programs. The study was published on March 10, 2020, in Radiology.

“We could clearly detect the increase of DNA damage and chromosome aberrations after standard chest CT. In contrast, no significant differences were observed in these biological effects before and after low-dose CT,” said senior author Satoshi Tashiro, MD, PhD, director of the Research Institute for Radiation Biology and Medicine at Hiroshima University. “Even using these sensitive analyses, we could not detect the biological effects of low-dose CT scans. This suggests that application of low-dose CT for lung cancer screening is justified from a biological point of view.”

In Japan, low-dose CT screening has been employed since the 1990s. However, unlike other countries, examinees include light smokers and non-smokers. As a result, a large number of stage one lung cancers are detected, and the survival rate is high.

Related Links:
Hiroshima University
Fukushima Medical University


Gold Member
Solid State Kv/Dose Multi-Sensor
AGMS-DM+
Dose Area Product Meter
VacuDAP
MRI System
uMR 588
New
Ultrasound Doppler System
Doppler BT-200

Print article

Channels

Ultrasound

view channel
Image: Structure of the proposed transparent ultrasound transducer and its optical transmittance (Photo courtesy of POSTECH)

Ultrasensitive Broadband Transparent Ultrasound Transducer Enhances Medical Diagnosis

The ultrasound-photoacoustic dual-modal imaging system combines molecular imaging contrast with ultrasound imaging. It can display molecular and structural details inside the body in real time without... Read more

Nuclear Medicine

view channel
Image: PET/CT of a 60-year-old male patient with clinical suspicion of lung cancer (Photo courtesy of EJNMMI Physics)

Early 30-Minute Dynamic FDG-PET Acquisition Could Halve Lung Scan Times

F-18 FDG-PET scans are a way to look inside the body using a special dye, and these scans can be either static or dynamic. Static scans happen 60 minutes after the dye is administered into the body, showing... Read more

Imaging IT

view channel
Image: The new Medical Imaging Suite makes healthcare imaging data more accessible, interoperable and useful (Photo courtesy of Google Cloud)

New Google Cloud Medical Imaging Suite Makes Imaging Healthcare Data More Accessible

Medical imaging is a critical tool used to diagnose patients, and there are billions of medical images scanned globally each year. Imaging data accounts for about 90% of all healthcare data1 and, until... Read more

Industry News

view channel
Image: The acquisition will expand IBA’s medical imaging quality assurance offering (Photo courtesy of Radcal)

IBA Acquires Radcal to Expand Medical Imaging Quality Assurance Offering

Ion Beam Applications S.A. (IBA, Louvain-La-Neuve, Belgium), the global leader in particle accelerator technology and a world-leading provider of dosimetry and quality assurance (QA) solutions, has entered... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.